Skip to main content
Premium Trial:

Request an Annual Quote

Cellectricon, AstraZeneca Will Consider Developing New Cell-based Microfluidic Screening Tool

NEW YORK, May 3 (GenomeWeb News) - Cellectricon and AstraZeneca will "study the possibility" of developing a new cell-based microfluidic screening platform, Cellectricon said today.


The collaboration specifically aims to improve cell-based ion-channel assays in screening applications, Cellectricon said.


Financial terms of the alliance were not disclosed.


This isn't the first time the companies have crossed paths. Last June, AstraZeneca installed several of Cellectricon's DynaFlow ion channels screening platforms worldwide.


Cell-Based Assay News, a GenomeWeb News sister publication, reported in June 2004 that AstraZeneca had decided to use DynaFlow in its ion channel drug-discovery program. Cellectricon said today that AstraZeneca has placed multiple orders for DynaFlow systems since that time.


DynaFlow is based on a computer-controlled microfluidic chip, and is designed to be used with any cell, patch-clamp configuration, active substance, and ion channel, Cellectricon said.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.